# Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Mucosal Leishmaniasis

> **NCT00111514** · PHASE1 · COMPLETED · sponsor: **Access to Advanced Health Institute (AAHI)** · enrollment: 48 (—)

## Conditions studied

- Leishmaniasis, Mucocutaneous

## Interventions

- **BIOLOGICAL:** Leish-111f + MPL-SE vaccine

## Key facts

- **NCT ID:** NCT00111514
- **Lead sponsor:** Access to Advanced Health Institute (AAHI)
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** —
- **Final completion:** 2006-05
- **Target enrollment:** 48 (—)
- **Last updated:** 2007-02-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00111514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00111514, "Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Mucosal Leishmaniasis". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT00111514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*